Literature DB >> 7031760

99mTc-DTPA and 131I-hippuran findings in liver transplant recipients treated with cyclosporin A.

G B Klintmalm, W C Klingensmith, S Iwatsuki, G P Schröter, T E Starzl.   

Abstract

The effects of cyclosporin A (CyA), an immunosuppressive agent that is potentially nephrotoxic, on the kidneys of 9 liver transplant recipients were studied with serial 99mTc-DTPA and 131I-hippuran scans. In addition, renal function was determined by measuring serum creatinine levels during the second postoperative week in the 9 unselected CyA-treated patients and, retrospectively, in a control group of 29 liver transplant recipients who had not been treated with CyA and who were selected because they had survived for at least 3 months postoperatively. The early postoperative creatinine level was significantly greater in the CyA group. Eight of the 9 CyA patients showed imaging abnormalities in all preoperative and postoperative studies. Five of the 8 patients showed a pattern similar to that of acute tubular necrosis (relatively preserved perfusion) in at least one study. Lowering the dosage of CyA permitted the continuation of therapy, and all 9 patients are alive after 8 to 14 months.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7031760      PMCID: PMC2956303          DOI: 10.1148/radiology.142.1.7031760

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  17 in total

1.  Biological effects of cyclosporin A: a new antilymphocytic agent.

Authors:  J F Borel; C Feurer; H U Gubler; H Stähelin
Journal:  Agents Actions       Date:  1976-07

2.  Cyclosporin A: preliminary observations in dogs with pancreatic duodenal allografts and patients with cadaveric renal transplants.

Authors:  R Y Calne; D J White; B D Pentlow; K Rolles; T Syrakos; T Ohtawa; D P Smith; P McMaster; D B Evans; B M Herbertson; S Thiru
Journal:  Transplant Proc       Date:  1979-03       Impact factor: 1.066

3.  Cyclosporin A for psoriasis.

Authors:  W Mueller; B Herrmann
Journal:  N Engl J Med       Date:  1979-09-06       Impact factor: 91.245

4.  Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.

Authors:  R Y Calne; K Rolles; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; R G Henderson; S Aziz; P Lewis
Journal:  Lancet       Date:  1979-11-17       Impact factor: 79.321

5.  Nephrotoxicity of cyclosporin A in liver and kidney transplant patients.

Authors:  G B Klintmalm; S Iwatsuki; T E Starzl
Journal:  Lancet       Date:  1981-02-28       Impact factor: 79.321

6.  Cyclosporin A in patients receiving renal allografts from cadaver donors.

Authors:  R Y Calne; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; B D Pentlow; K Rolles
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

7.  Cyclosporin A for the treatment of graft-versus-host disease in man.

Authors:  R L Powles; A J Barrett; H Clink; H E Kay; J Sloane; T J McElwain
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

8.  99mTc-DTPA renal studies for acute tubular necrosis: specificity of dissociation between perfusion and clearance.

Authors:  W S Shanahan; W C Klingensmith; R Weil
Journal:  AJR Am J Roentgenol       Date:  1981-02       Impact factor: 3.959

9.  Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin-A treatment.

Authors:  C J Green; A C Allison
Journal:  Lancet       Date:  1978-06-03       Impact factor: 79.321

10.  The use of cyclosporin A and prednisone in cadaver kidney transplantation.

Authors:  T E Starzl; R Weil; S Iwatsuki; G Klintmalm; G P Schröter; L J Koep; Y Iwaki; P I Terasaki; K A Porter
Journal:  Surg Gynecol Obstet       Date:  1980-07
View more
  6 in total

1.  Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506.

Authors:  S Takaya; O Bronsther; K Abu-Elmagd; H Ramos; J J Fung; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1993-06       Impact factor: 1.066

2.  Pediatric liver transplantation. Part II. Diagnostic imaging in postoperative management.

Authors:  R Dominguez; L W Young; J Ledesma-Medina; J Cienfuegos; J C Gartner; K M Bron; T E Starzl
Journal:  Radiology       Date:  1985-11       Impact factor: 11.105

3.  Hepatic perfusion abnormalities after liver transplantation.

Authors:  B A Porter; E S Woodle; R E Ward
Journal:  Cardiovasc Intervent Radiol       Date:  1985       Impact factor: 2.740

4.  Bone marrow transplantation: effects of conditioning and cyclosporin prophylaxis on microvascular permeability to a small solute (technetium 99m diethylene triamine penta-acetic acid).

Authors:  A M Peters; D S Vassilarou; J M Hows; F W Ballardie
Journal:  Eur J Nucl Med       Date:  1991

5.  Variable convalescence and therapy after cadaveric renal transplantation under cyclosporin A and steroids.

Authors:  T E Starzl; T R Hakala; J T Rosenthal; S Iwatsuki; B W Shaw
Journal:  Surg Gynecol Obstet       Date:  1982-06

6.  Renography and biopsy-verified acute rejection in renal allotransplanted patients receiving cyclosporin A.

Authors:  H S Thomsen; S L Nielsen; S Larsen; H Løkkegaard
Journal:  Eur J Nucl Med       Date:  1987
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.